Haishan Jang

653 total citations
14 papers, 522 citations indexed

About

Haishan Jang is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Haishan Jang has authored 14 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Radiology, Nuclear Medicine and Imaging, 4 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Haishan Jang's work include Erythropoietin and Anemia Treatment (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Biosimilars and Bioanalytical Methods (2 papers). Haishan Jang is often cited by papers focused on Erythropoietin and Anemia Treatment (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Biosimilars and Bioanalytical Methods (2 papers). Haishan Jang collaborates with scholars based in United States, Netherlands and Belgium. Haishan Jang's co-authors include Young Ki Min, Hugh M. Davis, Robert Stanley, Esther Bouman‐Thio, Qun Jiao, Stanley J. Marciniak, Honghui Zhou, Serge Rousselle, Carrie Wagner and Jeannie R. Rojas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Haishan Jang

13 papers receiving 493 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haishan Jang United States 8 166 133 118 117 102 14 522
Thomas A. Zanardi United States 10 115 0.7× 72 0.5× 286 2.4× 43 0.4× 76 0.7× 13 492
Karen Berry United States 9 471 2.8× 85 0.6× 144 1.2× 76 0.6× 127 1.2× 12 755
John Dulos Netherlands 14 259 1.6× 33 0.2× 196 1.7× 83 0.7× 63 0.6× 22 673
R. Loor United States 9 65 0.4× 63 0.5× 237 2.0× 59 0.5× 99 1.0× 15 688
Emanuela Fecarotta Italy 11 102 0.6× 29 0.2× 219 1.9× 277 2.4× 42 0.4× 20 547
J.P. Salier France 12 141 0.8× 84 0.6× 258 2.2× 62 0.5× 44 0.4× 30 538
Julie A. Lucas United States 14 695 4.2× 45 0.3× 217 1.8× 52 0.4× 91 0.9× 16 1.1k
Fujio Takeuchi Japan 18 214 1.3× 152 1.1× 510 4.3× 74 0.6× 153 1.5× 47 885
Alison Connor Canada 13 152 0.9× 37 0.3× 285 2.4× 36 0.3× 88 0.9× 17 550
Jennifer Fraszczak Canada 13 415 2.5× 34 0.3× 201 1.7× 64 0.5× 115 1.1× 23 725

Countries citing papers authored by Haishan Jang

Since Specialization
Citations

This map shows the geographic impact of Haishan Jang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haishan Jang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haishan Jang more than expected).

Fields of papers citing papers by Haishan Jang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haishan Jang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haishan Jang. The network helps show where Haishan Jang may publish in the future.

Co-authorship network of co-authors of Haishan Jang

This figure shows the co-authorship network connecting the top 25 collaborators of Haishan Jang. A scholar is included among the top collaborators of Haishan Jang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haishan Jang. Haishan Jang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Tsao, Yeou‐Ping, Conrad Tou, Frank Lee, et al.. (2021). Topical BRM421 Ophthalmic Solution improves signs and symptoms of moderate to severe dry eye patients in clinical trials. 62(8). 1335–1335. 1 indexed citations
2.
Yumul, Roma, Kamola Saydaminova, Hongjie Wang, et al.. (2016). Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic. Molecular Therapy — Methods & Clinical Development. 3. 16013–16013. 14 indexed citations
3.
Cui, Dan, et al.. (2012). [Expression of monocarboxylate transporter 8 mRNA in the brain tissue of rats with cerebral ischemia].. PubMed. 32(6). 913–5. 2 indexed citations
4.
Ruixo, Juan José Pérez, Wojciech Krzyżański, Esther Bouman‐Thio, et al.. (2009). Pharmacokinetics and Pharmacodynamics of the Erythropoietin Mimetibody™ Construct CNTO 528 in Healthy Subjects. Clinical Pharmacokinetics. 48(9). 601–613. 31 indexed citations
5.
Bouman‐Thio, Esther, Kari L. Franson, Bruce Miller, et al.. (2008). A Phase I, Single and Fractionated, Ascending‐Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects. The Journal of Clinical Pharmacology. 48(10). 1197–1207. 31 indexed citations
6.
Zhou, Honghui, Haishan Jang, Roy Fleischmann, et al.. (2007). Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis. The Journal of Clinical Pharmacology. 47(3). 383–396. 149 indexed citations
7.
Bugelski, Peter J., J. W. Fisher, Ian E. James, et al.. (2005). Pharmacokinetics and Pharmacodynamics of CNTO 528, a Novel Erythropoietin Receptor Agonist in Normal and Anemic Rats.. Blood. 106(11). 4261–4261. 4 indexed citations
8.
Rojas, Jeannie R., Ronald P. Taylor, Mark R. Cunningham, et al.. (2005). Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics. 313(2). 578–585. 107 indexed citations
9.
Martin, Pauline L., Qun Jiao, Joel B. Cornacoff, et al.. (2005). Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti-αv Integrin Monoclonal Antibody, Despite Widespread Tissue Binding. Clinical Cancer Research. 11(19). 6959–6965. 35 indexed citations
10.
11.
Davis, Hugh M., et al.. (2004). A rational approach for a phase I clinical study design to evaluate CNTO 95, a novel, fully human anti-avmonoclonal antibody (MAb), in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2609–2609. 2 indexed citations
12.
Jayson, Gordon C., et al.. (2004). Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3119–3119. 3 indexed citations
13.
Stanley, Robert & Haishan Jang. (1999). Electronic Structure Measurements of Oxidized Flavins and Flavin Complexes Using Stark-Effect Spectroscopy. The Journal of Physical Chemistry A. 103(45). 8976–8984. 31 indexed citations
14.
Jang, Haishan, et al.. (1994). Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women.. Arteriosclerosis and Thrombosis A Journal of Vascular Biology. 14(2). 275–281. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas A. Zanardi Breakdown of academic impact, for papers by Karen Berry Breakdown of academic impact, for papers by John Dulos Breakdown of academic impact, for papers by R. Loor Breakdown of academic impact, for papers by Emanuela Fecarotta Breakdown of academic impact, for papers by J.P. Salier Breakdown of academic impact, for papers by Julie A. Lucas Breakdown of academic impact, for papers by Fujio Takeuchi Breakdown of academic impact, for papers by Alison Connor Breakdown of academic impact, for papers by Jennifer Fraszczak
Rankless by CCL
2026